2009
Delhi (India)
Series E
DCDC Kidney Care, is a leading healthcare provider specializing in dialysis services for patients with end-stage renal disease (ESRD). Headquartered in New Delhi, India, the company operates over 200 dialysis centers across the country, serving more than 20,000 patients annually. Its services include in-center hemodialysis, home hemodialysis, peritoneal dialysis, and kidney transplant consultations. DCDC has positioned itself as a critical player in making life-saving dialysis treatments accessible and affordable, particularly for economically weaker sections through public-private partnerships (PPP) with state governments. The company’s unique value proposition lies in its commitment to quality care at affordable prices using standardized protocols. Notably, its "Nephrine Renal Care" center became the first standalone dialysis center in India to receive NABH accreditation, a testament to its adherence to high-quality standards. DCDC has also been recognized with prestigious awards such as the Frost & Sullivan "Dialysis Chain of the Year" (2018) and an International Business Award for being India’s most dependable dialysis suppliers.
DCDC Kidney Care generates revenue primarily through its dialysis services offered under two operational models:
Public-Private Partnerships (PPP): Collaborating with state governments to provide subsidized dialysis to low-income patients.
Standalone Clinics: Company-owned centers that cater to both middle-income and affluent customers.
The company’s monetization strategies include:
Reimbursements under government healthcare schemes like Ayushman Bharat.
Strategic partnerships with impact investors and development finance institutions.
DCDC serves a mixed customer base comprising B2C (individual patients) and B2G (government contracts).
Its growth strategy focuses on:
Market Expansion: Plans to roll out 150 new centers across India and expand internationally.
Technology Integration: Enhancing operational efficiency and patient care through advanced medical equipment.
Strategic Partnerships: Collaborating with global impact investors like British International Investment (BII) and ABC Impact to fund expansion efforts.
DCDC differentiates itself by focusing on underserved regions through PPPs and delivering high-quality care at lower costs. The company currently conducts nearly 100,000 dialysis sessions monthly, addressing critical gaps in accessibility for ESRD patients.
Hence, with its mission-driven approach and robust growth strategy, DCDC Kidney Care is poised to remain a key player in India's renal care sector while addressing critical healthcare challenges.
$61.7 Million
7
$17.4 Million, Series E
as of March 24, 2025
$29.8 Million
as of February 29, 2024
0.86
as of February 29, 2024
ABC Impact
and 2 more559
The Eye Vet
N/A
Date | Round Name | Amount | Valuation | Revenue | Revenue Multiple | Investors |
---|---|---|---|---|---|---|
March 24, 2025 | Series E | $17.4 Million | - | - | - | ABC Impact |
December 9, 2024 | Series D | $9.7 Million | - | - | - | British International Investment |
February 29, 2024 | Series C | $1.6 Million | $29.8 Million | $14.1 Million | - | IFU |
March 1, 2023 | Series C | $3.8M | $28.4M | $10 Million | - | IFU |
December 28, 2020 | Series C | $21.5 Million | - | $8.3 Million | - | IFU |
August 30, 2018 | Series B | $3.2 Million | $17.9 Million | $5.1 Million | - | Asian Development Bank |
September 10, 2014 | Series A | $4.4 Million | $12.5 Million | - | - | Pragati Capital |